Recent Developments In The Treatment Of (HBR) Patients

Published: 23 January 2021

  • Views:

    Views Icon 60952
  • Likes:

    Heart Icon 7

Overview

Full programme

Part 3 of 3

Chapter 3: High Bleeding Risk Patients: Identifying the ‘forgotten’ population – Do we have the tools?

Marie-Claude Morice, Roisin Colleran

Overview

Learn more about the most recent developments in the treatment of (HBR) patients with coronary artery disease through videos, interviews and panel discussions with renowned faculty from highly ranked institutions.

This programme is supported by:

Key Learning Objectives

  • To emphasize the importance of defining high bleeding risk in patients undergoing PCI
  • To increase identification of high bleeding risk patients and learn how to apply this in your clinical practice
  • To highlight the Onyx One Clinical Program, including sub-analysis and the relevance for your daily practice

More from this programme

Part 1

Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation (AF) – insights from the Onyx ONE program

Chapter 1: Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation (AF) – insights from the Onyx ONE program. Question 1: What is the new data from the Onyx ONE clinical program presented at TCT? Question 2: Why was AF patient population important to be included in a sub analysis? Question 3: What are the main findings of the AF sub analysis?

Part 2

Complex PCI with 1-month DAPT in HBR patients - insights from the Onyx ONE program

Chapter 2: Complex PCI with 1-month DAPT in HBR patients – insights from the Onyx ONE program. Question 1: Why was Complex PCI patient population important to be included in a sub analysis? Question 2: What are the main findings of the complex PCI sub analysis? Question 3: How relevant these data (both AF and complex PCI) are for your daily practice?

Part 3

High Bleeding Risk Patients: Identifying the ‘forgotten’ population – Do we have the tools?

In this video both physicians will discuss the importance of identification High Bleeding Risk patients, as also the specific mobile application (ARC HBR Application) that has been developed to quickly identify HBR patients at the bedside. Dr Colleran and Dr Morice will also look into the future and review the next steps the Academic Research Consortium is taking for the identification and treatment options for HBR patients undergoing PCI.

Faculty Biographies

Marie-Claude Morice

Marie-Claude Morice

Dr Marie-claude Morice has been head of the Insitiut Cardiovasculaire Paris Sud, since 1995. He is a guest speaker at all major international meeting of the European Society of Cardiology (ESC) the American Heart Association (AHA) and the American College of Cardiology (ACC). Dr Morice is an expert with the Regional Hospital Agency (ARH) and is Co-Director of the Paris course on revascularisation. He is a corresponding member of the Argentine Society of Cardiology and was elected Honorary Professor of the Universidad Del Salvador, Buenos Aires, Argentina in 2004. Dr Morice gained an MD in 1973 and a degree in cardiology in 1975.

View full profile
Roisin Colleran

Roisin Colleran

View full profile